Opthea Limited
(ASX:OPT) has completed patient enrolment in its ongoing Phase 1 dose escalation clinical trial of OPT-302 as a novel therapy for wet age-related macular degeneration.
The study is being run under an investigational new drug program with the Food and Drug Administration at 14 sites across the US.
The phase 1 trial is a first in-human, open label, sequential dose escalation study. The trial enrolled the target 20 patients into four treatment cohorts.
Detailed evaluation of longer term patient outcomes from the ongoing phase 1 dose escalation study is expected in the 3rd quarter of 2016.
Opthea recorded a net loss of $1.73 million at 31 December 2015.
